LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?

Novo Nordisk (NVO) and Eli Lilly (LLY) dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products.  Lilly markets its dual GIP and GLP-1 receptor agonist, tirzepatide, as Mounjaro for type II diabetes and as Zepbound for obesity. Novo Nordisk markets its semaglutide drugs as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes and as Wegovy injection for weight management.Lilly’s Cardiometabolic Health segment, which includes Mounjaro, Zepbound and ...